Decoding the S1P-S1PR axis in cancer: Mechanisms, pathways and therapeutic horizons (Review)

Yun-Ta Chuang1,2, I-Hui Wu3, Cheng-Fan Lee2

  • 1School of Medicine, University of Lancashire, Preston, Lancashire PR1 2HE, UK.

Biomedical Reports
|May 18, 2026
PubMed

Insights

Sphingosine-1-phosphate (S1P) signaling in cancer involves reprogramming of its receptors (S1PRs). Targeting both S1P production and S1PR signaling offers precise, biomarker-informed cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Sphingosine-1-phosphate (S1P) and its receptors (S1PR1-S1PR5) are crucial for normal physiological processes.
  • In cancer, the S1P-S1PR axis is dysregulated, impacting tumor progression, immune evasion, and metastasis.

Purpose of the Study:

  • To provide a receptor-specific review of S1PR functions in cancer.
  • To examine the mechanisms underlying S1P-S1PR axis dysregulation in tumors.
  • To discuss therapeutic strategies targeting this axis.

Main Methods:

  • Literature review synthesizing S1PR functions in cancer.
  • Analysis of mechanisms driving S1P-S1PR axis reprogramming.
  • Discussion of metabolic and receptor-level alterations.

Main Results:

  • Tumors reprogram the S1P-S1PR axis via altered S1P production and receptor dynamics.
  • Mechanisms include transcriptional, epigenetic, and post-translational modifications.
  • Metabolic amplification of S1P availability fuels tumor progression and resistance.

Conclusions:

  • The S1P-S1PR axis is a dynamically reprogrammed network in cancer.
  • Combined targeting of S1P production and S1PR signaling shows promise for cancer treatment.
  • Biomarker-informed strategies can enhance therapeutic precision.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...